Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

2023393 citationsJournal Articlebronze Open Access

Authors

Karim Fizazi · Université Paris-Saclay

Josep M. Piulats · Université Paris-Saclay

M. Neil Reaume · Université Paris-Saclay

Peter Ostler · Université Paris-Saclay

Ray McDermott · Université Paris-Saclay

Joel Roger Gingerich · Université Paris-Saclay

Elias Pintus ·

Abstract

The duration of imaging-based progression-free survival was significantly longer with rucaparib than with a control medication among patients who had metastatic, castration-resistant prostate cancer with a <i>BRCA</i> alteration. (Funded by Clovis Oncology; TRITON3 ClinicalTrials.gov number, NCT02975934.).

Topics & Keywords

PARP inhibition in cancer therapy Cell death mechanisms and regulation Prostate Cancer Treatment and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 388, Issue 8, pp. 719-732

DOI: 10.1056/nejmoa2214676

Field-Weighted Citation Impact: 90.06